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SuMMARy – diabetic nephropathy is a common complication in patients with diabetes me-
llitus and one of the major reasons for renal replacement therapy in Croatia, europe and the united 
States. it is characterized by proteinuria, decline in glomerular filtration, hypertension, and high risk 
of cardiovascular morbidity and mortality. deterioration of renal function in diabetic nephropathy 
develops through five clinical stages characterized by the respective histologic description. Genetic 
susceptibility, hyperglycemia, high blood pressure and duration of diabetes mellitus definitely play 
a role in the pathogenetic sequence. early diagnosis, appropriate patient follow up and treatment 
are essential to improve the outcomes. interdisciplinary approach and close collaboration of nephro-
logists and diabetologists are essential for timely detection of disease progression. Tight glycemic 
control under the supervision of diabetologists, screening of patients, and once a year report of albu-
minuria and glomerular filtration allow for detection of renal damage in the early stages and timely 
referral to a nephrologist. The points of interest given in this overview are description of clinical 
staging in relation to pathologic classification, repetition of basic causal features, and brief analysis 
of treatment.
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Introduction
diabetic nephropathy (dn) is the most common 
chronic complication in patients with type 1 and type 
2 diabetes mellitus, as well as in other, secondary 
forms of diabetes mellitus1,2. it is a major cause of end-
stage renal disease (eSRd) in europe3 and the united 
States4. According to the Registry of Renal Replace-
ment Therapy in 2012, Croatia follows global trends, 
so that dn was the primary renal disease in 29% of 
patients starting renal replacement therapy5. The rea-
son for the increased number of patients affected by 
dn with consequent eSRd lies in the growing world 
prevalence of diabetes mellitus among adults. Global 
estimates based on numerous studies predict an in-
crease from 6.4% and 285 million adults with diabetes 
mellitus in 2010 to 7.7% and 439 million in 2030, es-
pecially in developing countries6, despite the progress 
in diagnosis and treatment. diabetic nephropathy is 
one of the major risk factors for cardiovascular dis-
ease7,8 marked with albuminuria, decline in glomeru-
lar filtration rate (GFR) and hypertension9. 
Clinical Characteristics
Diabetic nephropathy is a slowly progressive and 
long time asymptomatic glomerulopathy10 character-
ized by structural changes in the form of glomerular 
basement membrane thickening, mesangial expansion, 
or finally glomerular sclerosis11,12. Functional charac-
teristics are based on hyperfiltration at the early stage, 
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moderately increased albuminuria (previously called 
microalbuminuria) with urine albumin excretion of 
30-300 mg/day, and severely increased albuminuria 
(previously called macroalbuminuria) with urine al-
bumin excretion above 300 mg/day. Albuminuria is 
still the only noninvasive marker of early dn develop-
ment. data have shown that the level of albuminuria 
need not be always associated with progression of the 
disease13, and low GFR without albuminuria was ob-
served in approximately 10% of patients with type 2 
diabetes mellitus14. There is still no convincing evi-
dence for such development of the disease. 
Pathogenesis
The pathogenesis of dn is multifactorial. Most 
frequently described factors that contribute to the de-
velopment and simultaneously influence the pathogen-
esis of dn are hyperglycemia, genetic susceptibility, 
high blood pressure and duration of diabetes mellitus. 
The advanced glycosylation end products (AGes) are 
formed by nonenzymatic process in excess of chronic 
hyperglycemia and thus accelerate the development of 
microvascular complications. hyperglycemia also ac-
tivates protein kinase C, which enhances permeability 
of the glomerular membrane for albumin and increas-
es the expression of transforming growth factor-beta 
(TGF-β), which is one of the crucial elements of tubu-
lointerstitial damage and glomerulosclerosis in dn15. 
hemodynamic changes in the kidney are mediated 
by several factors such as the renin-angiotensin sys-
tem, vascular endothelial growth factor (veGF), 
TGF-β, prostanoids and nitric oxide. Thereby im-
paired autoregulation of blood flow through the 
kidney leads to elevated hydraulic pressure in the 
glomerular capillaries, and consequently to afferent 
arteriolar vasodilatation, accompanied by vasocon-
striction of efferent arterioles, resulting in hyperfiltra-
tion, hypoperfusion and glomerular hypertension15. 
data from several studies on the pathogenetic se-
quence also point to the role of the transmembrane 
protein nephrin and its decreased expression, which 
leads to increased permeability of the glomerular 
membrane and ultimately to leakage of albumin16,17. 
however, a number of factors, as well as potential new 
markers are being investigated, which could help in the 
early detection and treatment of dn. Recent data have 
confirmed that bone morphogenic protein-7 (bMp-
7) expression and podocyte number are decreased in 
dn18. in dn, tubular cells produce a large amount of 
extracellular matrix proteins, which leads to intersti-
tial fibrosis. bMp-7 can reduce increased expression 
of interstitial extracellular matrix proteins19, so further 
investigations are required to determine the right posi-
tion of such findings and direction of next researches. 
Some authors are also focused on redefining the role 
and potential therapeutic strategies of antioxidative 
stress in dn20,21, whereas conventional antioxidants 
did not provide the expected benefits.
in the majority of patients, diagnosis is based on 
typical clinical presentation. in the situation of un-
usually rapid progression of renal disease in less than 
10-year duration of type 1 diabetes mellitus or rapid 
deterioration of GFR that cannot be explained by dn, 
presence of nephrotic range proteinuria at the time of 
diabetes diagnosis despite optimal blood pressure reg-
ulation, elevated serum creatinine without abnormali-
ties in urine, hematuria, active urinary sediment, and 
presence of other systemic disease including autoim-
mune disease22, renal biopsy should be performed as 
the gold standard, and therefore therapeutic approach 
is essentially different23. 
Retinopathy is easy to diagnose by fundus exami-
nation, and it is part of routine screening in diabetic 
patients. According to the KdoQi guidelines from 
2007, diabetic patients with proteinuria, retinopathy 
and renal impairment are considered to have dn, 
otherwise the causes of nondiabetic kidney disease 
should be examined22. 
Screening for nephropathy in patients with type 1 
diabetes, where the onset of disease is known, should 
be done about 5 years of diagnosis, while in patients 
with type 2 screening should be done immediately 
upon detection of the disease and then once a year 
by determining the rate of estimated GFR and albu-
minuria22.
A uniform classification of dn proposed by the 
Renal pathology Society has since recently been used 
in clinical practice. it is based on grading glomerular 
lesions from basement membrane thickening through 
mesangial expansion, the appearance Kimmelstiel-
Wilson lesions to ultimately advanced diabetic scle-
rosis. interstitial and vascular lesions are described 
separately12.
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Stages and Progression of Diabetic Nephropathy
deterioration of renal function in dn develops 
through 5 clinical stages24, which are characterized by 
histologic description below.
Stage 1 – hyperfiltration 
First stage is characterized by supranormal 
GFR of 125 to 140 ml min−1 1.73 m2, thus be-
ing called hyperfiltration. The prevalence ranging 
is variable; 40%-60% in type 1 diabetes and lower, 
mainly 0%-40% in type 2 diabetes25. it commonly 
develops 3-5 years from the onset of type 1 diabe-
tes mellitus, whereas in type 2 diabetes it can al-
ready be found at the time of diagnosis because the 
onset of disease is usually difficult to determine. 
To investigate the effect of hyperfiltration on fu-
ture development of nephropathy, Magee et al. 
have presented data from a meta-analysis in 780 
diabetic 1 patients, 130 of which developed neph-
ropathy; the median follow up in the studies was 
11.2 years. These results support the hypothesis 
that patients with hyperfiltration have an increased 
risk of further disease progression to nephropathy26. 
hyperfiltration is also closely related to the in-
creased kidney size, predominantly seen in type 1 
diabetes mellitus, due to hypertrophy of the tubules 
and interstitial expansion15. however, it is believed 
that changes occurring at this point are brief and re-
versible.
Stage 2 – ‘silent’ stage
This stage develops silently for up to 20 years. 
GFR is high or regular, albumin excretion and blood 
pressure are normal. in these patients, failure of blood 
pressure to decrease at night predicts further develop-
ment of albuminuria1,27. 
Some patients remain in this stage for lifetime. 
in addition, a study on fifteen adolescents with type 
1 diabetes, duration of more than 5 years, was aimed 
to investigate the relationship of specific factors in the 
development of morphological changes five years be-
fore kidney biopsy. data showed that basement mem-
brane thickness was predicted by 5-year mean hbA1c, 
diabetes duration and earlier GFR28. Thus, ultrastruc-
tural glomerular changes at this stage appear as a re-
sult of advancement during previous hyperfiltration. 
histologically presented thickening of the base-
ment membrane, as well as some clinical characteris-
tics overlap in the first and second stages.
Stage 3 – moderately increased albuminuria/
microalbuminuria/incipient nephropathy
According to the available data, in some patients 
there is genetic predisposition that determines de-
velopment of albuminuria and dn progression29. At 
this stage, albumin excretion of 30-300 mg over 24 h 
is expressed as hypertension in type 1 diabetes mel-
litus. in type 2 diabetes mellitus, hypertension may 
already be seen at the time of diagnosis. This stage 
develops after 6-15 years. observational data from 
a recent Japanese study on type 2 diabetes patients 
suggest that microalbuminuria and diabetic retin-
opathy are associated with fastest GRF decline30, 
which is consistent with earlier findings on gradual 
deterioration of renal function at this stage31. Al-
though timely detection of the disease, in particular 
albuminuria, and appropriate treatment are inevitable 
goals, there is evidence in support of the thesis that 
microalbuminuria may regress to normoalbuminuria 
in type 1 diabetes mellitus, regardless of angiotensin-
converting enzyme (ACe) inhibitors in therapy32. 
The changes found on biopsy specimens correspond to 
basement membrane thickening and mesangial ma-
trix expansion33.  
Stage 4 – severely increased albuminuria/overt 
nephropathy
Fourth stage usually develops after 10-25 years of 
the disease onset and is characterized by urinary al-
bumin excretion rate above 300 mg/day, an increased 
incidence of hypertension and further GFR reduction. 
Advanced histologic changes at renal biopsy with at 
least one Kimmelstiel-Wilson lesion can be seen. 
A higher mortality rate has been reported in a group 
of patients with developed albuminuria34, as well as 
progression to eSRd. however, recognition and 
influence on modifiable risk factors and aggressive 
treatment approach may reduce mortality by 30%35. 
in spite of all efforts, satisfactory pathogenetic ex-
planation of particular stages is not yet sufficiently 
known. 
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Stage 5 – end-stage renal disease  
After 10-30 years of diabetes mellitus diagnosis, 
progression to eSRd, with GFR <15 ml/min/1.73 m2 
may be expected. histologically, these changes corre-
spond to class iv and advanced glomerulosclerosis12. 
There is no significant difference in disease progres-
sion between type 1 and type 2 diabetes mellitus, as 
most patients die from cardiovascular complications 
before the onset of eSRd. in a subset of patients, de-
terioration of kidney disease occurs as a result of late 
disease detection on the one hand and diagnosis de-
lay due to temporary disappearance of hyperglycemia 
because of anorexia on the other hand15. in addition 
to conservative measures, treatment is carried out by 
hemodialysis, peritoneal dialysis, or kidney transplan-
tation. 
Kidney transplantation is the best option for suit-
able patients since it provides better survival than 
dialysis36 because of a decreased risk of fatal and 
non-fatal cardiovascular complications37. Atypical 
presentation of cardiovascular incidents should also 
be considered38.
in order to improve post-transplant graft and pa-
tient outcome, transplantation should be done as soon 
as possible and prior to initiating dialysis if possible, 
since interdependence has been observed between the 
increased mortality risk and graft loss and time spent 
on dialysis39; living donor kidney should be preferred 
to cadaveric kidney. 
The simultaneous kidney-pancreas transplantation 
is still debated because of more complications asso-
ciated with the increased morbidity and mortality, 
especially in type 2 diabetes mellitus, where properly 
selected patients with low cardiac risk can benefit, 
as opposed to type 1 where excellent results are re-
ported40,41. Therefore, diabetic patients have to un-
dergo detailed assessment of coronary disease, which 
in symptomatic subjects implies cardiac catheteriza-
tion, while others are advised to undergo dobutamine-
induced stress echocardiography. Attenuated physical 
condition is a limiting factor because of which exercise 
electrocardiography and exercise echocardiography 
are not suitable in dialysis patients42. if there is clinical 
suspicion of associated peripheral occlusive disease, it 
requires extensive diagnostic workup in consultation 
with vascular specialist.
in order to achieve the best results and bearing in 
mind the complexity of the problem, the transplanta-
tion team must have sufficient time to assess which is 
the best option for patients. 
Generally, after transplantation, urinary tract in-
fections are more often in these patients, while evi-
dence for other complications such as allograft rejec-
tion, malignancies or viral infection is still insufficient. 
Graft failure due to dn rarely occurs.
Treatment
Correction of dietary habits, lifestyle modifica-
tion including smoking cessation, and maintaining 
optimal body weight, and use of hypoglycemic agents 
to ensure hbA1c ~7.0% and renin-angiotensin system 
blockers constitute the framework for treatment of 
dn, all in order to reduce albuminuria and delay dis-
ease progression to eSRd. 
Glycemic control
The benefits of glycemic control in normalizing hy-
perfiltration and preservation of renal function have 
been previously described1,43,44. Results of large studies, 
uKpdS, dCCT and AdvAnCe, confirm the role 
of tight glycemic control in the development of mi-
croalbuminuria and progression of chronic kidney dis-
ease45-47. in the uKpdS study, this is achieved by re-
ducing hbA1c from 7.9% to 7.0% with intensified form 
of treatment, thus a target of near 7% hbA1c value has 
been implemented in the recommendations of the ma-
jority of professional societies because there is evidence 
that lower hbA1c values  (below 6%) are associated with 
an increased patient mortality45,48. Therapeutic options 
should be adjusted individually to each patient depend-
ing on the estimated glomerular filtration, in order to 
avoid hypoglycemia, which develops mainly due to im-
paired clearance of insulin and oral antidiabetic agents, 
as well as diminished kidney gluconeogenesis22.
The effect of strict glycemic control on renal out-
comes was exemplified on functional graft after pan-
creas transplantation during ten-year follow up. in 
eight patients with functional pancreas transplant, of 
which three patients had normal albumin excretion, 
three had moderately increased albuminuria and two 
had severely increased albuminuria before transplan-
tation, at five-year follow up renal function was stable 
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but without significant impact on histologic changes 
in the kidneys. however, after 10 years, changes in the 
glomeruli were retreated and renal function recovered49. 
optimal glycemic control, except for the effects on 
dn, is also particularly important to prevent wors-
ening of associated diabetic retinopathy and develop-
ment of blindness50.
Blood pressure control 
Several studies confirmed the importance of good 
blood pressure control and benefits of renin-angio-
tensin blockers. evidence from the uKpdS shows 
the beneficial effect of lowering blood pressure on the 
incidence of complications due to diabetes, as well as 
on the reduced risk of death due to diabetes51. in the 
irbesartan diabetic nephropathy trial, hypertensive 
diabetic 2 patients with nephropathy were random-
ized into irbesartan, amlodipine or placebo group; 
study data suggested that gradual lowering of systolic 
blood pressure to 120 mm hg was associated with im-
proved renal outcomes52. 
The latest AhA/eSC guidelines for the manage-
ment of arterial hypertension recommend lowering of 
systolic blood pressure to <130 mm hg (grade 2b), 
especially in the presence of overt proteinuria53, and 
in this respect renin-angiotensin blockers are better 
option than other antihypertensives (grade 1a)53,54.
The protective effect of these drugs on the kidney 
is a result of interaction of multiple factors55. dete-
rioration of the autoregulatory mechanism decreases 
resistance of afferent arterioles, resulting in enhanced 
total blood flow through the glomeruli and increased 
structural glomerular injury. Simultaneously with 
lowering of systemic hypertension, ACe inhibitors 
normalize glomerular capillary hydraulic pressure by 
dilatation of efferent arterioles52,56, achieve further 
reduction in proteinuria independent of blood pres-
sure55,57, and reduce production of collagen58, possibly 
due to the opposed effect of angiotensin ii and de-
creased stimulation of TGF-β55,59. 
other antihypertensive drugs should be added 
when indicated, with control of the relevant labora-
tory test results and regular blood pressure measure-
ment. preferred is a combination with diuretics (thi-
azide or loop diuretic depending on GFR), calcium 
channel blocker or beta-blocker, and drugs from other 
groups as necessary.
Correction of anemia
Treatment of anemia can delay the progression 
of eSRd and improve the quality of life of patients. 
Treatment with drugs that stimulate erythropoiesis 
should be started when other causes of anemia are 
excluded and hemoglobin value is less than 110 g/l, 
with target values of 110-120 g/l. hemoglobin val-
ues  above 120 g/l are not desirable because of the 
increased rate of cardiovascular complications. Simul-
taneously, iron preparations and b vitamins should be 
administered60-62. 
Treatment of dyslipidemia
Since dyslipidemia with diabetes and chronic 
kidney disease are risk factors for coronary heart dis-
ease, in case of failing to achieve target lipid values  by 
changing the habits, statin therapy should be intro-
duced22. in addition, Tonolo et al. in their study dem-
onstrated that lipid lowering may slow progression of 
chronic kidney disease, as well as of dn, probably via 
increased expression of nephrin, podocin, Cd2Ap, 
and FAT, alpha-actin proteins which are associated 
into lipid rafts. disabling the synthesis of cholesterol 
with statin plays an important role in modifying these 
lipid rafts63-68.
Novel agents
in order to improve treatment of dn and delay 
progression to eSRd, new therapeutic options are 
being investigated. one of the studies showed that, 
if combined with conventional therapy with renin-
angiotensin system blockers, vitamin d at a dose of 2 
mg/day successfully lowered residual albuminuria in 
patients with dn69; however, prior to its implementa-
tion in everyday practice, it will be necessary to wait 
for the results of further research. 
An interesting approach to the treatment of dn 
is the one focused on the mechanisms of oxidative 
stress and inflammation due to hyperglycemia. bar-
doxolone methyl is a synthetic triterpenoid that sig-
nificantly improves GFR, but raises blood pressure, 
encourages fluid retention and increases the inci-
dence of adverse cardiovascular events. hence, it is 
necessary to determine safety of these substances70. 
Sulodexide is an antifibrotic agent, which has the 
ability to decrease the production of TGF-β and thus 
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reduce the basement membrane permeability, but a 
larger study had to be terminated earlier as there was 
no difference compared to placebo71,72.
There have also been attempts to show the benefit 
of inhibition of AGe formation by pyridoxamine73 
and inhibition of protein kinase by ruboxistaurine74, 
and some recent studies have pointed to the use of 
baking soda in slowing the progression of renal func-
tion and improve the patient nutritional status75.
Conclusion
in the last decade, dn has been the leading cause 
of eSRd, identified as an important risk factor for 
high cardiovascular morbidity and mortality. Al-
though the understanding of dn pathogenesis has 
improved, it has not yet been fully clarified. early di-
agnosis, through close collaboration of nephrologists 
and diabetologists, correction of variable risk factors 
such as rigorous glycemia and blood pressure control, 
lifestyle modification, administration of statins and 
anemia rectification, along with proper monitoring of 
patient are still the core of each approach that increases 
the chances of survival in our patients. Kidney trans-
plantation is an optimal renal replacement therapy in 
well selected diabetic patients with dn and eSRd 
because it significantly improves the quality of life and 
reduces cardiovascular morbidity and mortality. Fur-
ther investigation of the novel agents are required to 
upgrade the treatment of patients with dn.
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Sažetak
novelA o diJAbeTičKoJ neFRopATiJi
R. Ivanac-Janković, V. Lovčić, S. Magaš, D. Šklebar i P. Kes
dijabetička nefropatija je najčešća komplikacija u bolesnika sa šećernom bolešću tip 2 i jedan je od najčešćih razloga 
za nadomještavanje bubrežne funkcije u hrvatskoj, europi i Sjedinjenim Američkim državama. obilježena je proteinu-
rijom, smanjenjem glomerularne filtracije te visokim srčano-žilnim pobolom i smrtnošću. oštećenje bubrežne funkcije u 
dijabetičkoj se nefropatiji razvija kroz pet kliničkih stadija s pripadajućim patohistološkim značajkama. u patogenetskom 
slijedu neosporna je uloga genetske predispozicije, hiperglikemije, arterijske hipertenzije i trajanja šećerne bolesti. in-
terdisciplinarni pristup i bliska suradnja nefrologa i dijabetologa neophodni su za pravodobno otkrivanje i napredovanje 
bolesti, a time i za poboljšanje ishoda bolesnika. Kontrola glikemije, probir bolesnika te jedanput godišnje određivanje 
albuminurije i glomerularne filtracije omogućava otkrivanje bubrežnog oštećenja u ranoj fazi i pravodobno upućivanje 
nefrologu. u ovome su radu prikazani klinički stadiji bolesti u korelaciji s patohistološkom klasifikacijom, ponovljene su 
osnove patogeneze i pristupa liječenju. 
Ključne riječi: Dijabetička nefropatija – dijagnostika; Dijabetička nefropatija – terapija; Albuminurija; Transplantacija bu-
brega; Pregledni rad
